 Privately-held Leading BioSciences Inc entered into a definitive agreement for a reverse merger with Seneca Biopharma Inc NASDAQ: SNCA has announced data from an open-label gastrointestinal GI surgery study with lead asset LB1148. Data provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. 